A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methoÂtrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…
Late 2021’s Awards, Appointments & Announcements in Rheumatology
Joan Von Feldt, MD, Named a PANLAR Master On Aug. 12, 2021, the Pan American League of Associations for Rheumatology (PANLAR) named Joan Von Feldt, MD, MSEd, FACR, FACP, MACR, a PANLAR Master. Dr. Von Feldt, a past president of the ACR (2015–16) and an emeritus professor of medicine at the Perelman School of Medicine,…
Harder to Breathe: The Infrastructure Behind Medical Oxygen
Last year, in Texas, they had no room to breathe. Texas has 301 designated trauma centers equipped to provide intensive care, 200 of which can care for at least four critically ill patients. In August 2021, 75 of these hospitals reported having no available beds in their intensive care units. Zero. This was due, in…
The NIAMS Diversity Supplement Program Offers Researcher Funding
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is a component of the National Institutes of Health (NIH) that supports research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases, as well as the training of basic and clinical scientists to carry out this research. NIAMS recognizes the…
State Legislative Issues to Watch in 2022
States increasingly take the lead on issues critical to our members and the field of rheumatology, including copay accumulator bans, white bagging restrictions, prior authorization and drug pricing.
2021 MIPS Reporting Submission Period Now Open
A 2021 MIPS Reporting Guide is available to help practices complete their MIPS dashboard and successfully report through the ACR’s RISE registry.
COVID-19 Vaccination in Patients with Rheumatic Disease
In January A&R, Simon et al. report a study to assess humoral and cellular immune responses after infection with, or vaccination against, SARS-CoV-2 in patients with B cell depletion and controls who are B cell competent, finding that B cell depletion completely blocks humoral but not T cell SARS-CoV-2 vaccination response. In the same issue, Connolly et al. evaluated disease flare and post-vaccination reactions in patients with rheumatic and musculoskeletal diseases following messenger RNA (mRNA) vaccination.
Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica
In a study, patients with new-onset polymyalgia rheumatica (PMR) who were treated with subcutaneous tocilizumab were more likely to achieve sustained, glucocorticoid-free remission than patients who received placebo.
New Healthcare Price Transparency Requirements Are Complicated & Vary by State
Healthcare law is ever changing, particularly with regard to price transparency. Key healthcare leaders and stakeholders have long argued for more stringent price transparency regulations in an effort to increase patient awareness regarding the cost of a hospital item or service prior to receiving the service. Such information is anticipated to enable patients to take…
Case Report: Elevated Inflammatory Markers & a Hypermetabolic Mass
Consulting rheumatologists often assess patients with atypical clinical presentations for the possibility of an underlying rheumatic disease. Inflammatory syndromes that are not clearly rheumatic in nature can be particularly challenging to diagnose. Here, we share the case of a young woman with a long-standing undiagnosed illness and highly elevated inflammatory markers, and describe the evaluation…
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 800
- Next Page »